Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report
Sarcopenia represents one of the hallmarks of all chronic disease, including non‐small cell lung cancer (NSCLC). A computed tomography scan is an easy modality to estimate the skeletal muscle mass through cross‐sectional image analysis at the level of the third lumbar vertebra (L3). Baseline skeleta...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.12965 |
| _version_ | 1819058323252576256 |
|---|---|
| author | Alessio Cortellini Lucilla Verna Giampiero Porzio Federico Bozzetti Pierpaolo Palumbo Carlo Masciocchi Katia Cannita Alessandro Parisi Davide Brocco Nicola Tinari Corrado Ficorella |
| author_facet | Alessio Cortellini Lucilla Verna Giampiero Porzio Federico Bozzetti Pierpaolo Palumbo Carlo Masciocchi Katia Cannita Alessandro Parisi Davide Brocco Nicola Tinari Corrado Ficorella |
| author_sort | Alessio Cortellini |
| collection | DOAJ |
| description | Sarcopenia represents one of the hallmarks of all chronic disease, including non‐small cell lung cancer (NSCLC). A computed tomography scan is an easy modality to estimate the skeletal muscle mass through cross‐sectional image analysis at the level of the third lumbar vertebra (L3). Baseline skeletal muscle mass (SMM) was evaluated using gender‐specific cutoffs for skeletal muscle index in NSCLC patients administered immunotherapy with nivolumab to evaluate its possible correlations with clinical outcomes. From April 2015 to August 2018, 23 stage IV NSCLC patients were eligible for image analysis. Nine patients (39.1%) had low SMM. Among patients with baseline low and non‐low SMM, median progression free survival was 3.1 and 3.8 months, respectively (P = 0.0560), while median overall survival was 4.1 and 13 months, respectively (P = 0.2866). This hypothesis‐generating preliminary report offers the opportunity to speculate about the negative influence of sarcopenia on immune response. In our opinion, nutritional status could affect the clinical outcomes of immunotherapy, even if we cannot make definitive conclusions here. Further studies on the topic are required. |
| first_indexed | 2024-12-21T13:53:22Z |
| format | Article |
| id | doaj.art-4198a57060c541989584176e0df05b87 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-21T13:53:22Z |
| publishDate | 2019-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-4198a57060c541989584176e0df05b872022-12-21T19:01:37ZengWileyThoracic Cancer1759-77061759-77142019-02-0110234735110.1111/1759-7714.12965Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary reportAlessio Cortellini0Lucilla Verna1Giampiero Porzio2Federico Bozzetti3Pierpaolo Palumbo4Carlo Masciocchi5Katia Cannita6Alessandro Parisi7Davide Brocco8Nicola Tinari9Corrado Ficorella10Medical Oncology, San Salvatore Hospital University of L'Aquila L'Aquila ItalyDepartment of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila ItalyMedical Oncology, San Salvatore Hospital University of L'Aquila L'Aquila ItalyFaculty of Medicine University of Milan Milan ItalyDepartment of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila ItalyDepartment of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila ItalyDepartment of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila ItalyMedical Oncology, San Salvatore Hospital University of L'Aquila L'Aquila ItalyClinical Oncology Unit S.S. Annunziata Hospital Chieti ItalyDepartment of Medical, Oral and Biotechnological Sciences University G. D'Annunzio Chieti ItalyMedical Oncology, San Salvatore Hospital University of L'Aquila L'Aquila ItalySarcopenia represents one of the hallmarks of all chronic disease, including non‐small cell lung cancer (NSCLC). A computed tomography scan is an easy modality to estimate the skeletal muscle mass through cross‐sectional image analysis at the level of the third lumbar vertebra (L3). Baseline skeletal muscle mass (SMM) was evaluated using gender‐specific cutoffs for skeletal muscle index in NSCLC patients administered immunotherapy with nivolumab to evaluate its possible correlations with clinical outcomes. From April 2015 to August 2018, 23 stage IV NSCLC patients were eligible for image analysis. Nine patients (39.1%) had low SMM. Among patients with baseline low and non‐low SMM, median progression free survival was 3.1 and 3.8 months, respectively (P = 0.0560), while median overall survival was 4.1 and 13 months, respectively (P = 0.2866). This hypothesis‐generating preliminary report offers the opportunity to speculate about the negative influence of sarcopenia on immune response. In our opinion, nutritional status could affect the clinical outcomes of immunotherapy, even if we cannot make definitive conclusions here. Further studies on the topic are required.https://doi.org/10.1111/1759-7714.12965ImmunotherapynivolumabNSCLCsarcopeniaskeletal muscle |
| spellingShingle | Alessio Cortellini Lucilla Verna Giampiero Porzio Federico Bozzetti Pierpaolo Palumbo Carlo Masciocchi Katia Cannita Alessandro Parisi Davide Brocco Nicola Tinari Corrado Ficorella Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report Thoracic Cancer Immunotherapy nivolumab NSCLC sarcopenia skeletal muscle |
| title | Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report |
| title_full | Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report |
| title_fullStr | Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report |
| title_full_unstemmed | Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report |
| title_short | Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report |
| title_sort | predictive value of skeletal muscle mass for immunotherapy with nivolumab in non small cell lung cancer patients a hypothesis generator preliminary report |
| topic | Immunotherapy nivolumab NSCLC sarcopenia skeletal muscle |
| url | https://doi.org/10.1111/1759-7714.12965 |
| work_keys_str_mv | AT alessiocortellini predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT lucillaverna predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT giampieroporzio predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT federicobozzetti predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT pierpaolopalumbo predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT carlomasciocchi predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT katiacannita predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT alessandroparisi predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT davidebrocco predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT nicolatinari predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport AT corradoficorella predictivevalueofskeletalmusclemassforimmunotherapywithnivolumabinnonsmallcelllungcancerpatientsahypothesisgeneratorpreliminaryreport |